KobeltGBergJLindgrenP. Costs and quality of life in multiple sclerosis in Europe: Method of assessment and analysis. Eur J Health Econ2006; 7(Suppl. 2): S5–13.
2.
KobeltGThompsonABergJ. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler2017; 23(8): 1123–1136.
3.
GiovannoniGButzkuevenHDhib-JalbutS. Brain health: Time matters in multiple sclerosis. Mult Scler Relat Disord2016; 9(Suppl. 1): S5–S48.
4.
AscherioAMungerKLLünemannJD.The initiation and prevention of multiple sclerosis. Nat Rev Neurol2012; 8(11): 602–612.
5.
HobartJKalkersNBarkhofF. Outcome measures for multiple sclerosis clinical trials: Relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. Mult Scler2004; 10(1): 41–46.
6.
OrmeMKerriganJTyasD. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health2007; 10(1): 54–60.
7.
StroberLChiaravallotiNMooreN. Unemployment in multiple sclerosis (MS): Utility of the MS Functional Composite and cognitive testing. Mult Scler2014; 20(1): 112–115.
BozkayaDLivingstonTPMigliaccio-WalleK. The cost-effectiveness of disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis. Value Health2015; 18(3): A283.
MarziniakMGhorabKKozubskiW. Variations in multiple sclerosis practice within Europe – Is it time for a new treatment guideline?Mult Scler Relat Disord2016; 8: 35–44.
12.
GiovannoniG.Why do you have to be lucky to get the MS treatment you deserve?Mult Scler Relat Disord2016; 8: A3–A4.
